A Phase 2 interventional study of GFT505 80mg and Placebo in Type II Diabetes Mellitus, sponsored by Genfit. Completed at 28 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-13.
Sponsored by Genfit · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 235 studies in Diabetes Mellitus, Type 2 with a site in Romania — 10 open to participants now, 18 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Romania.
Among the 235 studies in Diabetes Mellitus, Type 2 with a site in Romania, this one is the 216th largest by enrollment of the 228 interventional ones that give a count, is one of 25 that started in 2010, is one of 41 in phase 2, and was the 114th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →10 of the 235 studies in Diabetes Mellitus, Type 2 with a site in Romania are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Romania, United States, Brazil and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Romania, United States, Australia and 6 more countries
Ages 18–75
Novo Nordisk A/S · Sites in Romania, United States, Argentina and 16 more countries
Ages 18+
Hoffmann-La Roche · Sites in Romania, United States, Argentina and 19 more countries
Ages 18+
Boehringer Ingelheim · Sites in Romania, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
235 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 46 · Phase 3 160 · Phase 4 24
First in 2001; this study’s year is marked. 25 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 606 across the 228 interventional studies, 2,446 across the 7 observational. Of the 216 that completed or were terminated, 158 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
234 of 235 have an industry lead sponsor. The 10 most frequent:
Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Genfit has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Romania that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07668388Novo Nordisk A/SA Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | 2027-10-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 235 studies in Diabetes Mellitus, Type 2 with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is expected to demonstrate the anti-diabetic efficacy of 3-months treatment with GFT505 (80 mg/d) on Glycosylated Haemoglobin A1c (HbA1C) and fasting plasma glucose.
And to assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 for 12 weeks in patients with type 2 diabetes mellitus.
The study period per patient is 16-20 weeks maximum and is conducted as follows :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GFT505 80mg
Drug: Placebo
hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
hard gelatin capsules,oral administration,4 capsules per day before breakfast
HbA1c
To evaluate after 12 weeks of oral administration of double blind treatment the change from baseline in HbA1c level achieved with GFT505 80mg versus placebo. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).
Time frame: 12 weeks
Oral Glucose Tolerance Test (OGTT)
To evaluate the changes from baseline to end of treatment in OGTT parameters. Evaluation will be made prior the first treatment intake and 12 weeks after the first treatment intake.
Time frame: 12 weeks
Fasting Plasma Glucose
To evaluate the changes from baseline to end of treatment in fasting plasma Glucose. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).
Time frame: 12 weeks
Insulin resistance Index [fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR)]
To evaluate the changes from baseline to end of treatment in insulin resistance index. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).
Time frame: 12 weeks
The record gives a start of Dec 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor